313 related articles for article (PubMed ID: 29948178)
1. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
3. Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
Chuluunbat T; Chan RV; Wang NK; Lien R; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Ophthalmic Surg Lasers Imaging Retina; 2016 Dec; 47(12):1095-1105. PubMed ID: 27977832
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
7. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
Jin E; Yin H; Li X; Zhao M
Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
9. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
Zhang H; Yang X; Zheng F; Wan S; Xu Y
Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
[TBL] [Abstract][Full Text] [Related]
10. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
11. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
12. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema.
Shimura M; Yasuda K; Motohashi R; Kotake O; Noma H
Br J Ophthalmol; 2017 Nov; 101(11):1518-1523. PubMed ID: 28270488
[TBL] [Abstract][Full Text] [Related]
13. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
[TBL] [Abstract][Full Text] [Related]
16. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.
Zhang G; Yang M; Zeng J; Vakros G; Su K; Chen M; Li H; Tian R; Li N; Tang S; He H; Tan W; Song X; Zhuang R;
Retina; 2017 Apr; 37(4):710-717. PubMed ID: 27529839
[TBL] [Abstract][Full Text] [Related]
17. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1.
Kimyon S; Mete A
Ophthalmologica; 2018; 240(2):99-105. PubMed ID: 29920490
[TBL] [Abstract][Full Text] [Related]
19. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
[TBL] [Abstract][Full Text] [Related]
20. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
